07-07-2021, 02:28 PM
(This post was last modified: 07-07-2021, 02:30 PM by JackieDemmy.
Edit Reason: Trying to update references
)
Chemotherapy Reaction in Oncology
Created Feb 2021
Contact Information
Developed by: Demmy, Jackie
Developed for: BC Cancer Agency/Fraser Health Authority
Submitted by: JackieDemmy
Contact Email: simulation@fraserhealth.ca
Peer Reviewed: <strong>Yes</strong> (The information is provided below)
Scenario Information
Case Summary:
A 58-year-old patient with ovarian cancer is receiving a new infusion of GOOVCATM (paclitaxel and carboplatin). She develops back pain, weakness and hypotension. The team must recognize a moderate (Grade II) reaction, escalate to MRP, and manage the symptoms via medications, halt infusion, and plan restarting.
Target Learning Groups:
Physicians, Nursing, Specialist, Interprofessional Team
Additional Target Learning Groups:
Proposed Setting:
Fraser Health In-patient Oncology, BC Cancer Agency Chemotherapy
Educational Goals:
1. Recognizes moderate reaction to paclitaxel infusion and defines per grading scale (Grade II)
2. Differentiates between non-antibody mediated reaction (cytokine storm versus and anaphylaxis)
3. Utilizes available resources to manage infusion and treat reaction (supplied: BC Cancer Agency
Protocol for Management of Infusion-Related Reactions to Systemic Therapy Agents (2021))
4. Utilizes SBAR to report reaction to MRP
Peer Review Information
Clinical Content Peer Review
Clinical Content Reviewer: C Heywood Reviewed on: 02/21/2021
Notes on Clinical Content Peer Review:
Unknown
Simulation/Educational Review
Simulation/Educational Reviewer: Jackie Demmy Reviewed on: 07/06/2021
Notes on Simulation/Educational Peer Review:
Unknown
Simulation/Educational Real Time Review
Simulation/Educational Real Time Reviewer: Jackie Demmy Reviewed on: 02/22/2021
Notes on Simulation/Educational Real Time Peer Review:
Unknown
Extra Information
Additional Details:
References:
See scenario for references
Scenario Links:
BC Cancer Protocol Summary for Primary Treatment of No Visible Residual (Moderate-High Risk) Invasive Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer Using CARBOplatin and PACLitaxel
PROTOCOL CODE: SCDRUGRX Preprinted Order A: Immediate management of infusion-related reaction and resumption of infusion
BC Cancer Protocol Summary for Management of Infusion-Related Reactions to Systemic Therapy Agents
Additional Tags: Chemotherapy, reaction, cancer, cytokine storm
If you would like further information about this scenario please contact simulation@fraserhealth.ca or leave a comment below.